July 17--Baxter International Inc.'s second-quarter profit fell 11.8 percent to $520 million as a variety of one-time charges dragged down its bottom line.
Revenue in the quarter grew 16.1 percent to $4.3 billion, driven largely by contributions from its dialysis products acquired from Gambro AB.
Sales in its bioscience unit, which Baxter intends to split off into a separate, publicly traded company in mid 2015, rose 7 percent to $1.8 billion. Revenue in its medical products business, which includes the dialysis products portfolio, rose 24 percent to $2.5 billion.
Adjusted for certain one-time items, including costs associated with an infusion pump recall, the planned spin-off and integration of Gambro, earnings per share rose 6 cents to $1.26, beating Wall Street expectations by 4 cents.
The Deerfield-based medical products company said it remains on track to split into two by mid-2015.
Follow @peterfrost Follow @chibreakingbiz
(c)2014 the Chicago Tribune
Visit the Chicago Tribune at www.chicagotribune.com
Distributed by MCT Information Services